Last reviewed · How we verify
vaccination PPV23
At a glance
| Generic name | vaccination PPV23 |
|---|---|
| Sponsor | Walvax Biotechnology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy (PHASE2)
- Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma (PHASE4)
- Clinical Trial of Recombinant Pneumococcal Protein Vaccine (PHASE1)
- Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels (PHASE4)
- Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease (PHASE4)
- PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2) (PHASE4)
- SPAD in Adult Patients
- A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vaccination PPV23 CI brief — competitive landscape report
- vaccination PPV23 updates RSS · CI watch RSS
- Walvax Biotechnology Co., Ltd. portfolio CI